![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Lineage and Neurgain will collaborate on the clinical testing of Neurgain’s novel Parenchymal Delivery Injection system, OPC1 , which is designed to allow for the administration of cells to the spinal cord without stopping the patient’s respiration.
Lead Product(s): OPC1
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: OPC1
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Neurgain Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 08, 2021